Clinical Research Directory
Browse clinical research sites, groups, and studies.
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT
Sponsor: The First Affiliated Hospital of Soochow University
Summary
This randomized trial aimed at validating the efficacy and safety of low-dose decitabine, together with umbilical cord blood in PGF post allo-HSCT patients.
Official title: Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
16 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-08-01
Completion Date
2026-11-01
Last Updated
2023-06-09
Healthy Volunteers
No
Conditions
Interventions
decitabine
15 mg/m2 daily intravenously for consecutive 3 days
umbilical cord blood
MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6
Granulocyte-colony stimulating factor
Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L
Recombinant human thrombopoietin / thrombopoietin receptor agonist
Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L
Recombinant human erythropoietin
Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L